Share-based Payment Arrangement, Expense of PROVECTUS BIOPHARMACEUTICALS, INC. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PROVECTUS BIOPHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $312,775, a 67% decline year-over-year.
  • PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,281,326.
  • PROVECTUS BIOPHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $1,280,786.
  • PROVECTUS BIOPHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2016 was $0, a 100% decline from 2015.
  • PROVECTUS BIOPHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2015 was $670,576, a 480% increase from 2014.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,281,326 $312,775 -$636,630 -67% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $1,917,956 $322,070 +$322,070 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,595,886 $315,100 +$315,100 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $1,280,786 $331,381 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
Q3 2024 $949,405 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $0 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $0 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q3 2014 $115,645 -$26,665 -19% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2014 2014 Q3
Q3 2013 $142,310 +$142,310 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q3 2012 $0 -$3,368,950 -100% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $183,028 +$183,028 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2012 2012 Q2
Q3 2011 $3,368,950 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $0 01 Apr 2011 30 Jun 2011 10-Q 08 Aug 2012 2012 Q2

PROVECTUS BIOPHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,280,786 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2016 $0 -$670,576 -100% 01 Jan 2016 31 Dec 2016 10-K 31 Mar 2017 2016 FY
2015 $670,576 +$554,931 +480% 01 Jan 2015 31 Dec 2015 10-K 31 Mar 2017 2016 FY
2014 $115,645 -$26,665 -19% 01 Jan 2014 31 Dec 2014 10-K 31 Mar 2017 2016 FY
2013 $142,310 -$40,718 -22% 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2016 2015 FY
2012 $183,028 -$3,185,922 -95% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
2011 $3,368,950 -$390,700 -10% 01 Jan 2011 31 Dec 2011 10-K 13 Mar 2014 2013 FY
2010 $3,759,650 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.